Latest-3

An excellent summary about the potential of our lead program, OXU-001, from Drug Discovery World. “An innovative sustained release formulation of dexamethasone currently under investigation for use in DME offers the potential for effective anti-inflammatory treatment with significantly fewer injections and a high likelihood of fewer side effects, as its levels in the vitreous and …

Oxular in Drug Discovery World Read More »

Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal Space” at the December 2021 IOIS Conference. His talk included an update on a hard-to-treat postsurgical macular edema patient. The Oxulumis® posterior suprachoroidal microcatheter was used under compassionate use for the administration of Triesence®, an approved triamcinolone acetonide suspension. The …

2 x Triesence® doses; nearly one year of response Read More »